<DOC>
	<DOCNO>NCT01308034</DOCNO>
	<brief_summary>The purpose study determine safety continuous dose sunitinib association radiotherapy patient non GIST ( gastro intestinal stromal tumor ) sarcoma treat surgery . The primary objective study determine maximum tolerate dose ( MTD ) continuous dose sunitinib association radiotherapy patient non GIST sarcoma treat surgery . This study multicentre , open-label phase I dose escalation : 3 dose level . 3-6 patient include dose level.3-18 patient include study .</brief_summary>
	<brief_title>Study Continuous Dosing Sunitinib Non GIST Sarcomas With Concomitant Radiotherapy</brief_title>
	<detailed_description>Study design : 3 dose level Step 1 : 25 mg daily Step 2 : 37.5 mg daily Step 3 : 50 mg daily 3-6 patient include sunitinib dose level , depend number DLTs ( dose limit toxicity ) occur 14 week start treatment DLT define : grade 3 4 musculoskeletal cutaneous toxicity within field radiation toxicity &gt; = 4 Secondary objective : - evaluate safety late toxicity - estimate response rate 6 month - estimate progression free survival - evaluate proportion patient operable tumour treatment Exploratory objective : - study evolution treatment neo-angiogenesis measure dynamic contrast enhanced-ultrasonography ( DCE-US ) - study correlation clinical response change tumor perfusion measure DCE-US</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Male female patient &gt; 18 year age 2 . Histologically cytologically ( case recurrence ) confirm connective tissue neoplasm , include follow subtypes : Liposarcomas Fibrosarcoma , myxofibrosarcoma Undifferentiated pleomorphic sarcoma Leiomyosarcomas Pleomorphic rhabdomyosarcomas Angiosarcomas Uncertain differentiate tumor : synovial sarcoma , epithelioid sarcoma , alveolar sarcoma , clear cell sarcoma . osteosarcoma diagnosis , chondrosarcoma chordoma . 3 . Locally advanced locally recurrent inoperable tumor without previous irradiation [ inoperable status must assess staff include surgeon specialize sarcoma ] . 4 . No prior treatment sunitinib malate 5 . Life expectancy &gt; 6 month 6 . ECOG performance status ≤ 2 7 . Blood test , renal liver function normal range , 7 day prior study entry , blood serum value follow : Absolute neutrophil count ≥ 1.,5 G/L Platelet count ≥ 100 G/L Bilirubin ≤ 1.5 mg/dL PT INR ≤ 1.5 time upper limit normal [ Patients preventive anticoagulant therapy allow participate ] AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 150 umol/L Calcium ≤ 12 mg/dL Blood glucose &lt; 150 mg/dL 8 . Fertile patient must use effective contraception prior , , 28 day completion study therapy 9 . Ability swallow oral medication 10 . Mandatory affiliation health insurance company 11 . Signed write informed consent . 1 . GIST , Ewing sarcoma embryonic rhabdomyosarcoma 2 . Radiation field include lung , bowel , central nervous system 3 . Preexisting thyroid abnormality , define abnormal thyroid function test despite medication 4 . NCI grade ≥ 3 hemorrhage within past 4 week prior study drug administration 5 . Significant cardiovascular disease ( New York Heart Association ( NYHA ) &gt; grade 2 congestive cardiac failure , myocardial infarction within 6 month prior inclusion , unstable angina , severe cardiac arrhythmia , severe cerebrovascular accident within 6 month prior inclusion , history severe thromboembolism ( pulmonary embolism deep vein thrombosis DVT ) within 6 month prior inclusion ( patient recent history DVT treat anticoagulant ( except therapeutic warfarin ) least 6 week eligibles ) , prolong QTc interval ( QTc &gt; 480 msec Bazett ) , bradycardia ( heart rate &lt; 45bpm ) , electrolytic trouble ( hyponatremia &lt; 120mmol/l , kalemia≥6mmol/l ) uncontrolled hypertension receive appropriate medication ( ≥ 160 mm Hg systolic and/or ≥ 90 mm Hg diastolic ) . 6 . Less 6 week prior neoplastic treatment tyrosine kinase inhibitor inclusion le 4 week neoplastic treatment 7 . Major surgical procedure , open biopsy , serious non heal wound within 28 day prior first day treatment 8 . Concurrent participation another clinical trial 9 . Other disease illness within past 6 month prior study drug administration , include follow : Psychiatric illness social situation would preclude study compliance Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection 10 . Known brain metastasis , spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease 11. peritoneal carcinosis 12. number metastatic site &gt; 2 13 . Restriction freedom judicial administrative decision 14 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non GIST sarcoma</keyword>
	<keyword>sunitinib</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>dose escalation</keyword>
</DOC>